This short review provides a broad, and therefore necessarily incomplete and personal, overview of G-protein-coupled receptors, which are often targets for a wide range of important drugs: I will discuss successively their structure, function and interactions with associated proteins. Examples will be drawn from work done over the last 30 years by scientists that worked at different times in my laboratories, mainly in the field of β-adrenoceptors, muscarinic acetylcholine, melatonin and angiotensin receptors.
Introduction
The first group of GPCRs (G-protein-coupled receptors) to be well characterized were the β-adrenoceptors, of which there are three subtypes. All, however, respond to their natural ligands, adrenaline and noradrenaline, by activating adenylate cyclase, resulting in the production of cAMP, which is described as a second messenger, the agonist being the first. This activation is mediated by a GDP-binding heterotrimeric 'G' protein, hence the name GPCR. The β 1 subtype is expressed in the heart and is the target of the well-known beta-blocker drugs. Indeed, Sir James Black, who was awarded the Nobel Prize for Physiology or Medicine in 1988, discovered that antagonists to this type of receptor, such as propranolol, would be useful drugs to treat high blood pressure. β 2 receptors are expressed in the lung, trachea and uterus. Stimulation of β 2 receptors in the lung leads to bronchodilation: asthma patients can thus be treated with β 2 receptor agonists. Obviously, asthmatics who also have high blood pressure should be given beta-blockers that are highly selective for the β 1 subtype, and agonists highly selective for the β 2 subtype. Much less is known about the β 3 subtype, which was discovered by John Arch, and for a long time simply was known as 'beta-atypical'. It is now known to be expressed almost exclusively in adipose tissue, and may constitute a target for drugs to treat metabolic disorders. Professor Black also discovered cimetidine, which is a drug that targets specifically another GPCR, the H 1 subtype of histamine receptors.
By the 1970s, the growing interest in the function and pharmacology of GPCR receptors had led to detailed investigations of their structure. GPCRs were known to be intrinsic hydrophobic proteins, inserted in the plasma cell membranes, and thus notoriously hard to solubilize and purify in an active form. In 1977, my group, then at the Free University of Brussels in Belgium, published the first purification of a β-adrenoceptor using detergent solubilization, affinity chromatography and an immobilized antagonist, dihydroalprenolol, to isolate it from turkey erythrocyte membranes [1] . Adenylate cyclase was not retained specifically on the column, thus providing the first molecular evidence that this effector enzyme was not part of the adrenoceptor itself, but was a distinct protein activated by agonist binding to the receptor.
After that initial experiment, it took almost ten years to purify a number of similar receptors and to obtain their amino acid sequences. These sequences were observed to contain an unusual pattern of seven stretches of about 22-25 residues, each of which were particularly hydrophobic. It was soon realized that this was exactly the length of sequence necessary to cross a membrane when folded into an α-helix, and thus the idea arose that these stretches each corresponded to a transmembrane domain. The now-familiar 'seven-helical' GPCR structure, with the N-terminus region outside the cell, seven membrane-inserted helical segments separated by loops (including a fairly long one between the fifth and sixth helices) and an intracellular C-terminal domain, was proposed in one of the first papers on the cloning of a β-adrenoceptor gene [2] . This 'serpentine' structure, however, was not conceived out of the blue: it was based on that of the bacterial light receptor, bacteriorhodopsin, which was already known to have seven helical transmembrane domains. The structure of this protein was first predicted by Hargrave and co-workers using a helical wheel algorithm [3] . The structure is shown both perpendicular and parallel to the membrane in which the protein is embedded.
The knowledge that a human membrane receptor had a single-chain structure that could be described without too much difficulty led to a great deal of excitement, with scientists predicting that it would soon be possible to purify many of these proteins, obtain their three-dimensional crystal structures and perform useful structure-based drug design by docking potential ligands into their active-site clefts. Unfortunately, very few experimentally determined structures of seven-helical receptors are available, even now. In fact, the structure for only one mammalian protein, bovine rhodopsin, has been determined so far (e.g. see [4] ), and this has been used as the template for homology models of many other more pharmacologically interesting receptors, which were characterized in great numbers, as summarized in Figure 1 . The fact that, in rhodopsin, the ligand (retinal) is covalently bound to the receptor may explain why it has proved more tractable to structural studies than other receptors in its class. Predictions obtained by homology modelling are usefully tested experimentally using techniques such as affinity labelling and site-directed mutagenesis.
Structure and function of GPCRs
Knowing the sequences and the membrane topologies of both the β 1 and the β 2 adrenoceptors led us to investigate the way in which each of the transmembrane domains contributed to the β 1 or β 2 properties of the receptors. Stefano Marullo and his colleagues thus expressed both receptors in Escherichia coli. The β 1 receptor was gradually transformed into a β 2 receptor by swapping the sequence of each transmembrane domain in turn, first replacing the sequence of domain 1 with that of the same domain of the β 2 receptor, and then swapping further domains so that the sequence of the construct became closer and closer to that of β 2 . The results were more complex than expected: different residues seemed to be involved in binding and responding to different ligands [5] . This led to the theory that a conformational change is involved in ligand-receptor binding, and hence to the discovery of the mechanism of action of these receptors: that there is a protein, the heterotrimeric G-protein, that 'mediates' between the receptor and its effectors. G-proteins bind GDP, which is exchanged for GTP when the receptor has bound a ligand and therefore changed conformation. This simple idea, that the receptor modulates the activity of a G-protein that, in turn, modulates the activity of an effector molecule, is still very useful.
We do now understand how the receptor-bound ligand activates a G-protein which then modulates the effector protein. Heterotrimeric G-proteins consist of three subunits, known as α, β and γ . The exchange of GTP for GDP that occurs as a result of ligand-receptor binding causes the β and γ subunits to be released from the α subunit, which remains bound to the receptor. The β and β subunits are free to interact with effector molecules that are also bound to the membrane. The α subunit is, by itself, a very slow GTPase, and this activity returns it to its GDP-bound state in which it is free to combine with β and γ subunits and return to the beginning of the cycle; it can also interact with effectors. However, there remain a number of questions that this elegant model cannot answer, even today. These are mechanistic questions, concerning, for example, how the signal is transduced from the ligand-binding site on the outer side of the membrane to the G-protein-binding site in the interior, or how each very specific ligand-receptor interaction leads to a particular response via a fairly generic cascade of G-proteins, effectors and other associated proteins.
The GPCR superfamily is now one of the largest known families in the human genome, surpassing even the kinases [6] : based only on the predicted presence in the sequence of seven encoded hydrophobic stretches, there would be 865 potential GPCRs, a number which represents well over 3.5% of the human gene set now estimated at 23 000. The repertoire of Gproteins and downstream effector proteins is much smaller. Humans have, in total, 18 different G α subunits, five G β and eight G γ subunits, and each specifically activates one of also a small number of effectors.
The α subunit of the G-protein that transduces the activity of the β 1 and β 2 adrenoceptors is known as G αs , and it stimulates the activity of one of ten adenylate cyclases. Once adenylate cyclase has been stimulated, it produces cAMP, which in turn activates Protein A. Light-activated rhodopsin signalling is mediated by a different G α subunit, transducin, which stimulates cGMP phosphodiesterase. Other α subunits include the G i subunits, which inhibit adenylate cyclase but stimulate c-Src tyrosine kinases, G o , which activate phospholipase C, or G olf subunits that interact specifically with olfactory receptors. Identification of the receptor residues involved in coupling to G-proteins has been a systematic enterprise, different for each type or subtype of receptor; for example, Nathalie Blin and Jurgen Wess used domain swapping between two subtypes of muscarinic receptors to implicate residues in the second and third intracellular loops of these GPCRs in recognizing and binding to particular G i/o -α subunits [7] .
To investigate the role of receptor-G-protein association/dissociation, Stefano Marullo and co-workers constructed chimaeric proteins by fusing a GPCR with the α subunit of an interacting G-protein. This ability to study how the proteins could function if the G-protein is not allowed to dissociate from its partner has proven to be quite fruitful in a number of receptor/G-protein pairs. Creating these fusion proteins was also expected to be useful for structural studies, generating the hope that somehow the hybrid molecule containing the soluble G α protein would be easier to crystallize than the hydrophobic receptor alone [8] . Unfortunately, so far this has still not proven to be possible, even though several G α proteins have been crystallized by themselves.
Classifying GPCRs
The 865 seven-transmembrane, helix-encoded GPCR-like sequences identified in the human genome can be divided into two broadly defined functional classes: those homologous with sensory receptors, of which there are 360, and those more similar to non-sensory receptors, which constitute the remainder. Sensory receptors respond to stimuli that are perceived by the senses: smell, taste and light. Richard Axel and Linda Buck received the 2004 Nobel Prize in Physiology or Medicine for their work on odorant GPCRs and the organization of the olfactory system. They discovered that, unlike any other cell type expressing any other GPCR, each olfactory neuron expresses only one olfactory receptor. Odour perception thus results from the combined signalling of several different receptors situated on different neurons; few actual ligands have been identified so far.
Specific ligands have been identified for 210 of the 505 nonsensory GPCRs in the human genome. At least 150 of the others are currently described as 'orphan' receptors, meaning that their natural ligands are not yet known. Sixty of these, however, have been 'paired' with short peptides which are known to bind to them. although they may not be the natural ligands. As has been well shown for biogenic amine receptors, it is possible for one ligand to bind to several different receptor subtypes.
The GPCRs have been grouped into three families based on their sequences and ligand binding properties (Figure 2 ; [9] ). Family 1, the largest, includes the first GPCRs to be discovered; these GPCRs are closest in structure to rhodopsin since they have relatively short N-and C-termini. They 
GPCRs in the clinic and novel subtypes of potential clinical importance: the β 3 adrenoceptor
The GPCR superfamily is probably the most clinically important superfamily in the human genome. About half of the known molecular targets of drugs used in the clinic are GPCRs, and drugs targeted to these proteins have now been served to treat over 100 million patients. Approx. 30% of all patented drugs in current clinical use, and at least six of the top-selling 20 ethical pharmaceuticals target GPCRs, not counting drugs which are off patent, such as most betablockers and other biogenic amine ligands. The list of receptors targeted by useful drugs includes, besides the adrenoceptors, histamine, serotonin, dopamine, angiotensin and muscarinic acetylcholine receptors. More GPCR types and subtypes are still being added to this list, as can be illustrated by the case of the β 3 adrenoceptor. Laurent Emorine and his group discovered that the sequence of the β 3 adrenoceptor was about 45% identical with that of the β 2 receptor (Figure 3 ). It has a lower affinity than the other β-receptor subtypes for catecholamines, such as adrenaline, and also for conventional beta-blockers [10] . More interestingly, however, activators of lipolysis in white and brown adipose tissue are more potent on β 3 receptors than on either of the other subtypes, where several behave as antagonists rather than as agonists. This finding led to the idea that a compound that modulated β 3 adrenoceptor activity might have a role in treating obesity. However, exactly how such a drug might work is still open to question. One attractive hypothesis would be that agonists to the β 3 adrenoceptor would first stimulate proliferation of brown adipocytes before activating lipolytic thermogenesis in these cells. In support of this idea it was found that β 3 adrenoceptor is coupled to two types of G-proteins, G s and G i , and also to phosphoinositol kinases, thus permitting activation of several distinct signalling pathways.
In collaboration with geneticists we have, however, identified a mutation in this receptor in some obese patients, their families and a subgroup of Pima Indians known to be afflicted with diabetes and obesity. This mutation seems to be associated with exacerbation of obesity [11] . The β 3 receptor, which resists desensitization, may also play a role in protecting the myocardium during periods of intense catecholamine stimulation, such as heart failure, when the other β-receptors are desensitized.
Agonists to this receptor have indeed proved to reduce obesity in mice, rats and dogs, but this success has so far not been replicated in human clinical trials, possibly because of problems with bioavailability of the human β 3 receptorspecific compounds or because humans have less brown adipose tissue than rodents.
GPCR homo-and hetero-dimerization
We also now know that many GPCRs form homo-or heterodimers before or upon ligand binding, signal transduction or receptor internalization: dimerization can thus be quite important for the physiological function of the receptors [9] . In several experimental models, heterodimers have been shown to form between different subtypes activated by the same agonist, or even between receptors for different ligands. Dimerization may be necessary for the protein to be expressed in the membrane, to better bind a particular ligand, to transduce a signal (e.g. if one of the subunits has lost the ability to bind G-proteins), or for phosphorylation and internalization. Whether the dimerization observed in cells transfected with extraneous receptors always reflects true physiological situations, however, remains to be established.
Clara Nahmias and her group [13] have nicely illustrated the functional interaction between the AT 1 and AT 2 angiotensin receptors which bind the same angiotensin II ligand although they are only 35% identical, and have different physiological functions. The AT 2 receptor is constitutively active, but cannot bind G-proteins and is not internalized; the AT 1 receptor binds the G-protein G q . AT 1 signalling is inhibited when it forms a heterodimer with AT 2 through negative cross-talk, because the receptor subtypes modulate opposite signalling pathways, i.e. AT 1 induces proliferation, which is blocked by AT 2 . AT 2 was shown to be coupled to a tyrosine phosphatase and the two-hybrid-in-yeast method was used to identify an intermediate, possibly coupling protein: ATIP (angiotensin receptor-interacting protein) (Figure 4; [11] ). 
GPCR-interacting proteins
Until a few years ago it was thought that the interactions between GPCRs, G-proteins and their effectors could explain the whole system. However, we now know that it is much more complex, with many other proteins binding to GPCRs and influencing their activity; indeed, continued activation by an agonist leads to attenuation by desensitization, inactivation, internalization and recycling, involving a host of distinct proteins. The first examples of this 'complexification' were again identified through work on the β-adrenoceptors. It was thus discovered that certain protein kinases are able to phosphorylate these receptors, once adenylate cyclase has been activated and the G-protein released. An adaptor protein called β-arrestin then binds to the phosphorylated receptor, which 'tags' the protein for transport to the endosome, where it is either resensitized ('recycled') or destroyed. β-Arrestin, initially thought to be specific to the β-adrenoceptors, is also able to interact with other members of the GPCR family and is now frequently referred to as 'arrestin': four distinct arrestins have been shown to act as adaptors and scaffolds in addition to their role in desensitization of phosphorylated receptors [12] . Subsequent formation of multimolecular complexes initiated by binding to arrestin leads to activation of a variety of pathways involving diverse tyrosine or threonine/serine kinases, thus interconnecting GPCRs with a number of other pathways.
More recent work in the area of GPCR-associated proteins was done by Ralf Jockers and his group. This concerns a protein that interacts with the melatonin MT 1 receptor. This MUPP1 protein contains a large number of repeats of a 90-residue domain named PDZ, which is found in many signalling proteins; in fact, its name, MUPP1, comes from 'multi-PDZ protein'. One of these PDZ units binds to the C-terminal tail of the MT 1 receptor. Similar sequences have been found in over 50 different membrane proteins, most, but not all, of which are GPCRs.
There are, in fact, a great number of distinct but homologous PDZ proteins, which are found in various numbers, associated with other types of protein-protein interaction domains in a large variety of scaffold proteins. These bind to a large variety of GPCRs, including several subtypes of serotonin and metabotropic glutamate receptors, as well as β-adrenoceptors, dopamine receptors and others. Joel Bokaert has nicely illustrated the interactions that may link membrane receptors of various kinds through associated cytoplasmic adaptor and scaffold proteins [14] .
The network of proteins that interact with GPCRs may be particularly important for signalling, trafficking and targeting these receptors to particular cellular compartments, which have been termed 'signalosomes' or, when located in synapses, 'synaptosomes'. Different types of connections to different types of receptors allow both positive and negative cross-talk, and this fine-tuning allows the cell to respond differently to ligand binding. The fact that we have so far been unable to model this complexity in assays may explain why we are still unable to reliably design GPCR-targeted drugs that will be free of side effects.
